Cancer Research The Future of Cancer Research: Science and Patient Impact Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 3588-3591, August 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xie, Y.
Right arrow Articles by Larsson, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xie, Y.
Right arrow Articles by Larsson, O.
[Cancer Research 59, 3588-3591, August 1, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Expression of Insulin-like Growth Factor-1 Receptor in Synovial Sarcoma

Association with an Aggressive Phenotype1

Yuntao Xie, Björn Skytting, Gunnar Nilsson, Bertha Brodin and Olle Larsson2

Cellular and Molecular Tumor Pathology, Karolinska Hospital, SE-171 76 Stockholm [Y. X., B. S., G. N., B. B., O. L.]; Department of Orthopedics, Stockholm Söder Hospital, SE-100 64 Stockholm [B. S.]; and Department of Orthopedics, Karolinska Hospital, SE-171 76 Stockholm [G. N.], Sweden


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
It is well known that insulin-like growth factor-1 receptor (IGF-1R) plays a crucial role in proliferation and survival of transformed cells. Overexpression of IGF-1R in certain tumors has been reported, but there is still little known about its importance in vivo. Here, we evaluated the IGF-1R levels in 35 human synovial sarcoma tumors by Western blot and reverse transcriptase-PCR. In 18 of these, IGF-1R was detectable by Western blot, whereas 17 were nondetectable. There was a significant association between the amount of receptor proteins and mRNA transcripts. Furthermore, we found that the IGF-1R Western blot-positive tumors were associated with a high incidence of lung metastases. Eleven of 18 (61%) developed metastases in the IGF-1R detectable group, compared to 3 of 17 (18%) in the nondetectable group (P = 0.01). Moreover, in the detectable group of IGF-1R, 12 of 18 (67%) exhibited a high tumor cell proliferative rate, compared to 5 of 16 (31%) in the nondetectable group (P = 0.04). On the other hand, no association was found between the IGF-1R and type of fusion gene transcript (SYT-SSX1 or SYT-SSX2). Our results suggest that expression of IGF-1R can underlie an aggressive phenotype in synovial sarcoma.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Synovial sarcoma, which accounts for 5–10% of all soft tissue sarcomas, is primarily located in the extremities and can occur at any age, including childhood, but it is most commonly found in young adults (1) . Surgery is the main treatment, often supplemented with radiotherapy. Synovial sarcomas primarily metastasize to the lung, ultimately leading to death of the patient. Both thoracic surgery and chemotherapy have been shown to be of limited value. Although excellent local control has been reported from sarcoma centers, long-term survival rates have, at best, been reported to ~50% (2) . Characteristic for synovial sarcoma is the translocation t(X;18)(p11.2;q11.2) (SYT-SSX; Ref. 3 ), resulting in one of three types of fusion transcripts, SYT-SSX1, SYT-SSX2 (4) , or SYT-SSX4 (5) . Recently, it has been reported that type of fusion transcript may be of prognostic significance (6 , 7) .

IGF-1R3 is a plasma membrane-bound heterotetrameric receptor, composed of two {alpha}-subunits (Mr 130,000) and two ß-subunits (Mr 90,000 each), linked by disulfide bonds with intrinsic tyrosine kinase activity (8) . Evidence has been provided that the IGF-1R plays a crucial role in tumor cell growth in several different ways, such as mediating mitogenesis and maintaining a transformed phenotype, as well as protecting tumor cells from apoptosis (9, 10, 11) . Overexpression of the IGF-1R reduces growth factor requirements and the susceptibility to apoptosis (12) . Conversely, impairment of the IGF-1R function by antisense strategies, antibodies, or dominant negative mutants causes large-scale apoptosis of tumor cells, abrogation of tumor growth, and metastasis (13) .

IGF-1R is highly expressed in a number of different tumor tissues, such as breast cancer, osteosarcoma, and melanoma (12 , 14, 15, 16) . Studies on breast cancer have suggested that overexpression of IGF-1R is associated with local tumor recurrence (12) . Few studies on IGF-1R and the insulin-like growth factor-1 pathway have been performed on soft tissue sarcomas. In this study, we determined the IGF-1R levels by Western blot and RT-PCR in 35 synovial sarcoma tumors. Furthermore, we investigated whether there was an association between IGF-1R and incidence of lung metastasis.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Patients.
From 1988 to 1998, 35 patients with histologically verified localized synovial sarcoma were referred to Scandinavian Sarcoma Group centers. There were 17 males and 18 females, with a mean age at diagnosis of 40 years. RT-PCR confirmed that all cases carried SYT-SSX fusion transcripts. All patients underwent surgery with a curative intent. Adjuvant radiotherapy was administered to 17 patients, and 6 patients received chemotherapy. The mean follow-up period was 46 months (range, 2–111 months). Fourteen patients developed lung metastases during the follow-up period. Twenty-nine of the total number of cases were included in another study focusing on the association between type of SYT-SSX fusion transcript and clinical out-come (6) .

Cell Line.
A Ewing’s sarcoma cell line, RD-ES (HTB-166), was obtained from the American Type Culture Collection (Manassas, VA) and used as control. Cells were cultured routinely in RPMI 1640 with 10% FCS and maintained at 37°C in a humidified 5% CO2 atmosphere.

RT-PCR: Quantification of IGF-1R mRNA Levels.
Total RNA was isolated from the tumor specimens and the control cell line according to the manufacturer’s protocol (Qiagen, Hilden, Germany). Five hundred ng of total RNA were reverse-transcribed using random hexadeoxynucleotide primer (Pharmacia, Uppsala, Sweden). The PCR using IGF-1R primers (5'-GCCCGAAGGTCTGTGAGGAAGAA-3' and 5'-GGTACCGGTGCCAGGTTATGA-3') and ß-actin primers (5'-CATGCCATCCTGCTGGAC-3' and 5'-CACGGAGTACTTGCGCTCAGGAGG-3') was performed at 94°C for 30 s, 60°C for 30°C s, and 72°C for 30 s for 28, 30, and 32 cycles, followed by a final elongation for 10 min. PCR products were electrophoresed on 2% agarose and NuSieve gel, visualized by ethidium bromide staining, and quantified by densitometry (MultiAnalyst; Bio-Rad, Hercules, CA). The kinetics of the various reactions were evaluated using the control cell line cDNA to determine the optimal cycle numbers, ensuring that the PCR productions of IGF-1R as well as the internal control ß-actin remained exponential (data no shown).

Because the quantity of amplified ß-actin product is assumed to be proportional to the amount of initial mRNA template, a relative amount of IGF-1R product could be determined by normalizing IGF-1R amount to ß-actin. Finally, the relative value of IGF-1R expression in synovial sarcoma specimens was normalized to the level of the positive control cell line (15 , 17) .

Detection of SYT-SSX Fusion Gene Transcripts.
A primer SSX-A 5'-CACTTGCTATGCACCTGATG-3' was used for reverse transcription. The cDNA was amplified by PCR with SYT primer 5'-AGACCAACACGCCTGGACCA-3' and SSX primer 5'-TGCTATGCACCTGATGACGA-3'. After the amplification, the PCR products were directly sequenced by cycle sequencing with dye-labeled terminators (BigDye Terminators; Perkin-Elmer, Norwalk, CT) and analyzed on an ABI Prism 377XL DNA sequencer (Perkin-Elmer Applied Biosystems, Foster City, CA) to discriminate the two fusion types.

Western Blot.
Tumor samples were washed twice with cold PBS, and 100–200 mg of tumor tissues were homogenized on ice by lysis buffer. After centrifugation at 600 x g for 10 min at 4°C, the supernatants, containing the cellular proteins, were used for analysis. The protein concentrations were assessed by dye-binding Bio-Rad protein assay. For all specimens, the same amount of total protein (450 µg) was loaded on the SDS-polyacrylamide gel and analyzed using a 4% stacking gel and a 7.5% separating gel. Coomassie Brilliant Blue staining was used to check the amount and quantity of tumor proteins. Western blot using a rabbit polyclonal against the IGF-1R {alpha}-subunit (Santa Cruz Biotechnology, Santa Cruz, CA) was performed as described elsewhere (18) . The density of IGF-1R bands was assessed using the MultiAnalyst software.

Ki-67 Analysis.
Immunostaining with Ki-67 antibody (MIB-1; Immunotech, Marseilles, France) on corresponding samples was performed according standard avidin-biotin complex technique (Elite Standard Kit; Vector Laboratories, Burlingame, CA). The percentages of Ki-67-positive nuclei were determined as described previously (19) . Specimens with a Ki-67 index of <10% were considered to have a low proliferation rate, and specimens with a Ki-67 index of >=10% were regarded as highly proliferative (19) .


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
Analysis of IGF-1R Expression in Synovial Sarcoma by Western Blot and RT-PCR.
There were considerable differences in the signal intensity among the cases analyzed by Western blot (Fig. 1A)Citation . Corresponding samples were stained with Coomassie Brilliant Blue to ensure that the quality and amounts of the fractionated proteins did not differ between the cases. As shown in Fig. 1BCitation , the electrophoretic pattern and the intensity at the protein bands were essentially similar. The IGF-1R signals detected by Western blot in all 35 cases were quantified by densitometry. The obtained values are presented in Table 1Citation . Eighteen cases were found to have detectable signals for the IGF-1R protein.



View larger version (98K):
[in this window]
[in a new window]
  		Fig. 1. A, IGF-1R protein was analyzed by Western blot, using an antibody against the {alpha}-subunit of IGF-1R. The same amount of total protein was loaded for all samples. B, protein samples were stained with Coomassie Brilliant Blue. The same amount of total protein was loaded on the gel.

 

View this table:
[in this window]
[in a new window]
  		Table 1 IGF-1R correlation with lung metastasis, fusion gene type, and Ki-67 in synovial sarcomas

 
IGF-1R gene expression was analyzed by RT-PCR. Fig. 2Citation shows the IGF-1R PCR products from 6 of the 35 cases and the control cell line. Using densitometry, we determined the relative amount of transcripts for all cases (Table 1)Citation . The value for the control cell line (RD-ES) was set at 1.00. The relative values ranged from 0.01 to 1.26 among the cases. The association between the amount of IGF-1R proteins obtained by densitometry of Western blot signals and IGF-1R transcripts obtained by RT-PCR is shown in Fig. 3ACitation . There was a significant association noted (r = 0.68, P = 0.03). Nineteen of the 35 (54%) cases had RT-PCR values of >=0.50, which is in good concordance with the 18 cases with positive Western blot.



View larger version (39K):
[in this window]
[in a new window]
  		Fig. 2. IGF-1R gene expression in six samples and the control cell line. Total mRNA were reverse-transcribed and then amplified with IGF-1R and ß-actin primers for 28, 30, and 32 cycles.

 


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 3. A, association of Western blot and RT-PCR data. B, association of IGF-1R with lung metastases. C, association of IGF-1R with high-level Ki-67. D, association of IGF-1R with the SYT-SSX1 fusion gene.

 
IGF-1R Association with Metastatic Disease, Tumor Cell Proliferation, and Fusion Transcript.
In accordance with the Western blot results, the patients were divided into IGF-1R detectable and nondetectable groups (Table 1)Citation . In the detectable group, 11 of 18 (61%) developed lung metastases, as opposed to 3 of 17 (18%) in the nondetectable group ({chi}2 test, P = 0.01; Fig. 3BCitation ). We also found in the IGF-1R detectable group that 12 of 18 (67%) exhibited high Ki-67 values, compared with 5 of 16 (31%) in the nondetectable group (P = 0.04; Fig. 3CCitation ). In contrast, there was no association between IGF-1R and the fusion gene transcript SYT-SSX1 (P = 0.80; Fig. 3DCitation ).


   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
To date, there have been few studies on the role of the IGF-1R pathway in sarcoma, and most of these have been undertaken on bone tumors, i.e., osteosarcoma and Ewing’s sarcoma (14 , 15) . Burrow et al. (14) reported that ~50% of osteosarcoma tumors express high levels of IGF-1R. In a study by Scotlandi et al. (20) , it was shown that the IGF-1R-mediated loop was the only growth factor circuit that was constantly present in several Ewing’s sarcoma cell lines and clinical samples. They also showed that the IGF-1R-neutralizing antibody {alpha}IR-3 significantly inhibited the ability of Ewing’s sarcoma cells to grow in soft agar as well as their mobility. IGF-1R and insulin-like growth factor-1 have been found to be expressed in some soft tissue sarcomas, e.g., malignant fibrous histiocytoma and liposarcoma (15) . However, to our knowledge, no studies have shown any association between IGF-1R and the malignancy potential in sarcomas.

Here, we determined the level of IGF-1R in 35 synovial sarcoma samples. IGF-1R expression was independently evaluated by Western blot and RT-PCR. Analysis with Western blot showed that 51% of the cases expressed the receptor protein. There was a significant concordance between the protein and mRNA levels.

Invasion and metastasis are the most life-threatening aspects of malignant disease. In synovial sarcoma, metastatic lesions develop in ~50% of the cases and often appear several years after the initial diagnosis. The principal site of metastasis is the lung (1) . Our results show that 61% of the patients whose tumors were expressing IGF-1R developed lung metastases, compared to 18% in the IGF-1R nondetectable group. These findings strongly suggest that synovial sarcomas expressing IGF-1R have an aggressive phenotype. Similar results demonstrated for breast cancer suggest that IGF-1R is prognostic. In a series of patients with breast cancers, Turner et al. (12) found high levels of IGF-1R in 52% of the tumors. These cases relapsed more frequently within 4 years after diagnosis compared to cases with low IGF-1R expression. However, the role of this receptor in regulation of invasion/metastasis has not been fully elucidated. The process of metastasis involves multiple sequential interactions between the disseminating tumor cells and host tissues. Animal models have demonstrated that overexpression of IGF-1R results in an increase of metastatic potential. H-59 is an example of a highly metastatic variant of the Lewis lung carcinoma. When these tumor cells were transfected with an IGF-1R antisense RNA plasmid, they lost their ability to metastasize to lung or liver (21) . In another model using the M-27 carcinoma cells, an increase of the expression of the IGF-1R was found to enhance invasiveness and increase liver-colonizing potential (22) . Similar results have been reported by Burfeind et al. (23) , using a rat prostate cancer model. Recently, functional impairment of the IGF-1R in two different estrogen receptor-negative breast cancer cell lines was shown to suppress adhesion and invasive ability, resulting in fewer distant metastases in vivo (24) .

Here, we also found that IGF-1R was associated with a high rate of tumor cell proliferation. No relationship was found between the IGF-1R and type of fusion transcript (SYT-SSX or SYT-SSX2). SYT-SSX1 has recently been implicated as a marker for poor clinical outcome (6 , 7) . Therefore, it seems likely that IGF-1R and SYT-SSX1 fusion transcript affect the biological behavior of synovial sarcoma through different and independent pathways. An approach to the mechanisms underlying the aggressive phenotype in synovial sarcomas expressing IGF-1R makes an interesting issue for further research.


   ACKNOWLEDGMENTS
 
The following were responsible for supplying tumor material, reporting primary patient data, and performing follow-up: Henrik C. F. Bauer, Oncology Service, Department of Orthopedics, Karolinska Hospital, Stockholm, Sweden; Lars-Gunnar Kindblom, Department of Pathology, Sahlgren University Hospital, Gothenburg, Sweden; Örjan Berlin, Department of Orthopedics, Sahlgren University Hospital, Gothenburg, Sweden; Pelle Gustafson, Department of Orthopedics, Lund University Hospital, Lund, Sweden; Martti Virolainen, Department of Pathology, Helsinki University Hospital, Helsinki, Finland; and Carl Blomqvist and Riika Huuhtanen, Department of Radiotherapy and Oncology, Helsinki University Hospital, Helsinki, Finland.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 A Scandinavian Sarcoma Group study. Supported by the Swedish Cancer Society, the Cancer Society in Stockholm, the Lundberg Research Foundation in Gothenburg, and grants from the Karolinska Institute. Back

2 To whom requests for reprints should be addressed, at Cellular and Molecular Tumor Pathology, CCK R8:04, Karolinska Hospital, SE-171 76 Stockholm, Sweden. Fax: 46 8 321047; E-mail: olle.larsson{at}onkpat.ki.se Back

3 The abbreviations used are: IGF-R, insulin-like growth factor-1 receptor; RT-PCR, reverse transcriptase-PCR. Back

Received 5/10/99. Accepted 6/17/99.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Enzinger F. M., Weiss S. W. Soft Tissue Tumors Ed. 3 Mosby St. Louis 1995.
  2. Choong P. F., Åkerman M., Willen H., Andersson C., Gustafson P., Alvegard T., Rydholm A. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotype-specific?. APMIS, 103: 797-805, 1995.[Medline]
  3. Clark J., Rocques P. J., Gill S., Shipley J., Chan A. M., Gusterson B. A., Cooper C. S. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat. Genet., 7: 502-508, 1994.[Medline]
  4. Crew J., Clark J., Fisher C., Gill S., Grimer R., Mitchell P. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J., 14: 2333-2340, 1995.[Medline]
  5. Skytting B., Nilsson G., Brodin B., Xie Y., Lundeberg J., Uhlén M., Larsson O. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J. Natl. Cancer Inst., 91: 974-975, 1999.[Free Full Text]
  6. Nilsson G., Skytting B., Xie Y., Brodin B., Perfekt R., Mandahl N., Lundeberg J., Uhlén M., Larsson O. The SYT-SSX1 variant of synovial sarcoma is associated with high rate of tumor cell proliferation and poor clinical outcome. Cancer Res., 59: 3180-3184, 1999.[Abstract/Free Full Text]
  7. Kawai A., Woodruff J., Healey J. H., Brennan M. F., Antonescu C. R., Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N. Engl. J. Med., 338: 153-160, 1998.[Abstract/Free Full Text]
  8. Massague J., Czech M. P. The subunit structure of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J. Biol. Chem., 257: 538-545, 1992.
  9. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth?. Cancer Res., 55: 249-252, 1995.[Abstract/Free Full Text]
  10. Renicoff M., Burgaud J-L., Rotman H. L., Abraham D., Baserga R. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res., 55: 3739-3741, 1995.[Abstract/Free Full Text]
  11. Resnicoff M., Abraham D., Yutanawiboonchai W., Rotman H. L., Kajstura J., Rubin R., Zoltick P., Baserga R. The insulin-link growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res., 55: 2463-2469, 1995.[Abstract/Free Full Text]
  12. Turner B. C., Haffty B. G., Narayanan L., Yuan J., Havre P. A., Gumbs L. K., Burgaud J-L., Carter D., Baserga R., Glaazer P. M. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res., 57: 3079-3083, 1997.[Abstract/Free Full Text]
  13. Krzystof R., D’Ambrosio C., Tu X., Tu C., Baserga R. Inhibition of tumor growth by a dominant negative mutant of the insulin-link growth factor I receptor with a bystander effect. Clin. Cancer Res., 4: 2647-2655, 1998.[Abstract]
  14. Burow S., Andrulis I., Pollak M., Bell R. S. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J. Surg. Oncol., 69: 21-27, 1998.[Medline]
  15. Sekyi-Out A., Bell R. S., Ohashi C., Pollak M., Andrulis I. L. Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Res., 55: 129-134, 1995.[Abstract/Free Full Text]
  16. Kanter-Lewensohn L., Dricu A., Wang M., Wejde J., Kiessling R., Larsson O. Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target. Melanoma Res., 8: 389-397, 1998.[Medline]
  17. Noonan K. E., Beck C., Holzmayer T. A., Chin J. E., Wunder J. S., Andrulis I. L., Gazdar A. F., Willman C. L., Griffith B., Von Hoff D. D., Roninson I. B. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. USA, 87: 7160-7164, 1990.[Abstract/Free Full Text]
  18. Dricu A., Carlberg M., Wang M., Larsson O. Inhibition of N-linked glycosylation using tunicamycin causes cell death in human malignant cells: role of down-regulation of the insulin-like growth factor-1 receptor in induction of apoptosis. Cancer Res., 57: 543-548, 1997.[Abstract/Free Full Text]
  19. Skytting, B., Bauer, H. C., Perfekt, R., Nilsson, G., and Larsson, O. Ki-67 is strongly prognostic in synovial sarcoma. Analysis based on 86 patients from the Scandinavian Sarcoma Group Register. Br. J. Cancer, in press, 1999.
  20. Scotlandi K., Benini S., Sarti M., Serra M., Lolloni P-L., Maurici D., Picci P., Manara M. C., Baldini N. Insulin-like growth factor I receptor-mediated circuit Ewing’s sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res., 56: 4570-4574, 1996.[Abstract/Free Full Text]
  21. Long L., Rubin R., Baserga R., Brodt P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res., 55: 1006-1009, 1995.[Abstract/Free Full Text]
  22. Long L., Rubin R., Brodt P. Enhanced invasion and colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp. Cell Res., 238: 116-121, 1998.[Medline]
  23. Burfeind P., Chernicky C. L., Rininsland F., Ilan J., Ilan J. Antisense RNA to the type 1 insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc. Natl. Acad. Sci. USA, 93: 7263-7268, 1996.[Abstract/Free Full Text]
  24. Dunn S. E., Ehrlich M., Sharp J. H., Reiss K., Solomon G., Hawkins R., Baserga R., Barrett J. C. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res., 58: 3353-3361, 1998.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 The OncologistHome page
P. D. Ryan and P. E. Goss
The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer
Oncologist, January 1, 2008; 13(1): 16 - 24.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
X. Wan and L. J. Helman
The Biology Behind mTOR Inhibition in Sarcoma
Oncologist, August 1, 2007; 12(8): 1007 - 1018.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Zundelevich, G. Elad-Sfadia, R. Haklai, and Y. Kloog
Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid)
Mol. Cancer Ther., June 1, 2007; 6(6): 1765 - 1773.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Endocr. Rev., February 1, 2007; 28(1): 20 - 47.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S.-H. Oh, O.-H. Lee, C. P. Schroeder, Y. W. Oh, S. Ke, H.-J. Cha, R.-W. Park, A. Onn, R. S. Herbst, C. Li, et al.
Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.
Mol. Cancer Ther., November 1, 2006; 5(11): 2685 - 2695.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Bjorndahl, R. Cao, L. J. Nissen, S. Clasper, L. A. Johnson, Y. Xue, Z. Zhou, D. Jackson, A. Jon Hansen, and Y. Cao
Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo
PNAS, October 25, 2005; 102(43): 15593 - 15598.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Terry, J. M. Lubieniecka, W. Kwan, S. Liu, and T. O. Nielsen
Hsp90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Prevents Synovial Sarcoma Proliferation via Apoptosis in In vitro Models
Clin. Cancer Res., August 1, 2005; 11(15): 5631 - 5638.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. D. Wu, A. Odman, L. M. Higgins, K. Haugk, R. Vessella, D. L. Ludwig, and S. R. Plymate
In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors
Clin. Cancer Res., April 15, 2005; 11(8): 3065 - 3074.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Ahlen, J. Wejde, O. Brosjo, A. von Rosen, W.-H. Weng, L. Girnita, O. Larsson, and C. Larsson
Insulin-Like Growth Factor Type 1 Receptor Expression Correlates to Good Prognosis in Highly Malignant Soft Tissue Sarcoma
Clin. Cancer Res., January 1, 2005; 11(1): 206 - 216.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Guillou, J. Benhattar, F. Bonichon, G. Gallagher, P. Terrier, E. Stauffer, N. de Saint Aubain Somerhausen, J.-J. Michels, G. Jundt, D. R. Vince, et al.
Histologic Grade, But Not SYT-SSX Fusion Type, Is an Important Prognostic Factor in Patients With Synovial Sarcoma: A Multicenter, Retrospective Analysis
J. Clin. Oncol., October 15, 2004; 22(20): 4040 - 4050.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Tamborini, L. Bonadiman, A. Greco, A. Gronchi, C. Riva, R. Bertulli, P. G. Casali, M. A. Pierotti, and S. Pilotti
Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor {beta} Tyrosine Kinase Receptors in Synovial Sarcoma
Clin. Cancer Res., February 1, 2004; 10(3): 938 - 943.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
O. Stoeltzing, W. Liu, N. Reinmuth, F. Fan, A. A. Parikh, C. D. Bucana, D. B. Evans, G. L. Semenza, and L. M. Ellis
Regulation of Hypoxia-Inducible Factor-1{alpha}, Vascular Endothelial Growth Factor, and Angiogenesis by an Insulin-Like Growth Factor-I Receptor Autocrine Loop in Human Pancreatic Cancer
Am. J. Pathol., September 1, 2003; 163(3): 1001 - 1011.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. K. Maloney, J. L. McLaughlin, N. E. Dagdigian, L. M. Garrett, K. M. Connors, X.-M. Zhou, W. A. Blattler, T. Chittenden, and R. Singh
An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation
Cancer Res., August 15, 2003; 63(16): 5073 - 5083.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. V. Allander, P. B. Illei, Y. Chen, C. R. Antonescu, M. Bittner, M. Ladanyi, and P. S. Meltzer
Expression Profiling of Synovial Sarcoma by cDNA Microarrays : Association of ERBB2, IGFBP2, and ELF3 with Epithelial Differentiation
Am. J. Pathol., November 1, 2002; 161(5): 1587 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Xie, B. Skytting, G. Nilsson, A. Gasbarri, K. Haslam, A. Bartolazzi, B. Brodin, N. Mandahl, and O. Larsson
SYT-SSX Is Critical for Cyclin D1 Expression in Synovial Sarcoma Cells: A Gain of Function of the t(X;18)(p11.2;q11.2) Translocation
Cancer Res., July 1, 2002; 62(13): 3861 - 3867.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
C. All-Ericsson, L. Girnita, S. Seregard, A. Bartolazzi, M. J. Jager, and O. Larsson
Insulin-like Growth Factor-1 Receptor in Uveal Melanoma: A Predictor for Metastatic Disease and a Potential Therapeutic Target
Invest. Ophthalmol. Vis. Sci., January 1, 2002; 43(1): 1 - 8.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Ladanyi, C. R. Antonescu, D. H. Leung, J. M. Woodruff, A. Kawai, J. H. Healey, M. F. Brennan, J. A. Bridge, J. R. Neff, F. G. Barr, et al.
Impact of SYT-SSX Fusion Type on the Clinical Behavior of Synovial Sarcoma: A Multi-Institutional Retrospective Study of 243 Patients
Cancer Res., January 1, 2002; 62(1): 135 - 140.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Yu and T. Rohan
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression
J Natl Cancer Inst, September 20, 2000; 92(18): 1472 - 1489.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Girnita, A. Girnita, B. Brodin, Y. Xie, G. Nilsson, A. Dricu, J. Lundeberg, J. Wejde, A. Bartolazzi, K. G. Wiman, et al.
Increased Expression of Insulin-like Growth Factor I Receptor in Malignant Cells Expressing Aberrant p53: Functional Impact
Cancer Res., September 1, 2000; 60(18): 5278 - 5283.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xie, Y.
Right arrow Articles by Larsson, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xie, Y.
Right arrow Articles by Larsson, O.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online